Assessment of Macrophage Activation syndromE in STill's Disease
About the study
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- * Age \>6 months and ≤80 years at the beginning of the index MAS episode.
- * Diagnosis of Still's disease (sJIA (systemic Juvenile Idiopathic Arthritis) or AOSD (Adult Onset Stills Disease) diagnosis).
- * Diagnosis of MAS according to treating physician in the medical record.
- * Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition .
- * The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022.
EXCLUSION CRITERIA
Exclusion Criteria:
- * A diagnosis of primary Hemophagocytic Lymphohistiocytosis (HLH) prior to the beginning of the index MAS episode.
- * Confirmed malignancy prior to the beginning of the index MAS episode.
- * Patient treated with any investigational product as a part of clinical trial during the index MAS episode.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Macrophage Activation Syndrome,Still's Disease, Adult-Onset,Stills Disease, Juvenile-Onset
Age (in years)
6 - 80
Participants Needed
80
Est. Completion Date
Sep 19, 2024
Treatment Type
OBSERVATIONAL
Sponsor
Swedish Orphan Biovitrum
ClinicalTrials.gov NCT Identifier
NCT06405152
Study Number
Sobi.Emapalumab-105
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?